GENT: Strong EBITDA and fCAL turbo growth offset China sales softness; NT-proBNP advances clinically

About this update from Gentian Diagnostics Asa

Q3 2024 delivered strong EBITDA and improved gross margin, despite soft revenue growth due to lower China sales. fCAL turbo sales surged 76% year-over-year, and NT-proBNP assay advanced in clinical evaluation with a new patent granted.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Gentian Diagnostics Asa